Alphamab Oncology, a leading biopharmaceutical company in China, has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical study for its drug candidate, JSKN003. This study, identified as JSKN003-202, will focus on the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, collectively known as platinum-resistant ovarian cancer $(PROC)$. The study will be randomized, open-label, and multi-center. This advancement highlights Alphamab Oncology's proprietary protein engineering expertise and commitment to developing next-generation biological drug candidates. The company has not specified any collaboration with other organizations regarding this regulatory approval.